
A few days after receiving pivotal European approval for its migraine drug Vyepti, Lundbeck is moving ahead with another candidate for the treatment of migraines.
On Monday, the pharmaceutical company reports that preparations have been made for a phase II study to commence with the drug candidate Lu AG09222, which is a treatment for the prevention of migraines like Vyepti.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app